Accenture Board Insight - Generative AI

Its impact on the modern world has been compared to that of the personal computer and the iPhone. Its adoption is said to imperil millions of jobs and to revolutionise the way our businesses operate.
 
So how are we to handle the way we use Generative AI? And can it really change the way we will live, work and play?

This insight by Criticaleye Partner Accenture looks at five key questions that Board directors should consider in relation to AI.

Key takeaways include:
  • 98 percent of senior executives believe AI will play a key role in their businesses over the next three to five years.
  • Six out of 10 operations have planned to use Chat GPT for learning, with more than half planning to invest in the technology before the end of 2023.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
The Road to Renewables

Thomas Thune Andersen, former Chair of Ørsted, reflects on a decade of transformative leadership. He talks to Criticaleye’s Emily Jones about steering the Danish company’s business model from fossil f...

Click here to download this insight
Change Reinvented

In today's business landscape, continuous change is the new reality and navigating it effectively is essential to activating strategy and moving organisations forward. In this research, Criticaleye Partner, Accen...

Click here to download this insight
A New Frontier for Leadership

Business models are changing as companies seek to move faster and get closer to their customers. That’s certainly been the case for Lorenzo Simonelli, Chair and CEO of Baker Hughes, as he drives a bold strategy to...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 2,058




E.ON UK Royal London Group Redwood Bank Drax Group plc Experian London Stock Exchange Lightsource bp Eton Bridge Partners Google Legal & General Investment Management Eightfold AI Mayborn Group Tullow Oil plc Workday Bunzl plc Salesforce LDC Concentrix Veolia Water Technologies Robert Walters Accenture AlixPartners Amazon UK GlaxoSmithKline plc NATS